30 Apr 2024
Quarterly Activities/Appendix 4C Cash Flow Report
24 Apr 2024
Entitlement Offer - Offer Booklet
16 Apr 2024
Proposed issue of securities - ATX
16 Apr 2024
Entitlement Offer Cleansing Statement
16 Apr 2024
Rights Issue Investor Slide Deck
16 Apr 2024
Fully Underwritten 2 for 5 Entitlement Offer to raise $4.27
12 Apr 2024
Trading Halt
10 Apr 2024
AACR Conference Presentation
27 Mar 2024
Update on ACCENT Trial in Pancreatic Cancer
KAZ3y-I4wNk
30 Jan 2024
Quarterly Activities/Appendix 4C Cash Flow Report
18 Jan 2024
FDA Clearance Amplia's IND for Pancreatic Cancer Trial in US
OZFWlTCU5ys
17 Jan 2024
Amplia Reports First Patient Dosing In Phase 2a Accent Trial
02 Jan 2024
Change of Director's Interest Notice - Dr Warwick Tong
02 Jan 2024
Change of Director's Interest Notice - Dr Chris Burns
02 Jan 2024
Change of Director's Interest Notice - Dr Robert Peach
02 Jan 2024
Change of Director's Interest Notice - Jane Bell
02 Jan 2024
Notification of cessation of securities - ATX
02 Jan 2024
Application for quotation of securities - ATX
04 Dec 2023
Approval to Initiate Phase2 Pancreatic Cancer Trial in Korea
21 Nov 2023
Appendix 4D and Financial Report Half Year ended 30 Sep 23
31 Oct 2023
Quarterly Activities/Appendix 4C Cash Flow Report
30 Oct 2023
Promising Clinical Data 1b ACCENT Trial in Pancreatic Cancer
19 Oct 2023
Amplia Receives R&D Tax Rebate Totalling $ 2.4 Million
09 Oct 2023
AACR Ovarian Cancer Conference Presentation
29 Sep 2023
AACR Pancreatic Cancer Conference Presentation
25 Sep 2023
New Chief Financial Officer Mr Tim Luscombe
04 Sep 2023
Notification of cessation of securities - ATX
01 Sep 2023
Notification of cessation of securities - ATX
01 Sep 2023
Change of Director's Interest Notice - Dr Robert Peach
29 Aug 2023
Change of Director's Interest Notice - Dr Christopher Burns
29 Aug 2023
Notification regarding unquoted securities - ATX
24 Aug 2023
Results of Annual General Meeting
24 Aug 2023
CEO and MD Presentation to Annual General Meeting
02 Aug 2023
ACCENT Trial Recruitment Update
31 Jul 2023
ATX Quarterly Activities and Cashflow Reports - June 23 Qtr
21 Jul 2023
Notice of Annual General Meeting/Proxy Form
20 Jul 2023
ATX - Shareholder Newsletter July 2023
12 Jul 2023
Application for quotation of securities - ATX
21 Jun 2023
AMP945 International Nonproprietary Name Narmafotinib
19 Jun 2023
Amplia AGM to be held Thursday 24 August 2023
31 May 2023
Key to Corporate Governance Disclosures
30 May 2023
2023 Corporate Governance Statement
30 May 2023
Annual Report to Shareholders
29 May 2023
AMP945 and FOLFIRINOX active in model of Pancreatic Cancer
23 May 2023
Grant to collaborate with CSIRO Supplementary Announcement
22 May 2023
Amplia receives grant to collaborate with CSIRO
09 May 2023
ACCENT Trial Recruitment Progress
26 Apr 2023
Quarterly Activities and Cashflow Reports - March 23 Qtr
19 Apr 2023
First Patient Recruited to Cohort 3 of ACCENT Trial
11 Apr 2023
Dose Escalation Approved in ACCENT Clinical Trial of AMP945
28 Feb 2023
ACCENT Trial Recruitment Progress
23 Feb 2023
ATX - US Conference Presentation
09 Feb 2023
AmpliaTherapeutics - Lorne Cancer Conference Presentation
01 Feb 2023
First Patient Recruited to Cohort 2 of Accent Trial
30 Jan 2023
Quarterly Activities and Cashflow Reports - December 2022
11 Jan 2023
Dose Escalation Approved in ACCENT Clinical Trial of AMP945
20 Dec 2022
Letter to Shareholders End of Year Summary and 2023 Plans
01 Dec 2022
Final Director's Interest Notice - Dr. John Lambert
29 Nov 2022
ACCENT Trial Recruitment Progress
18 Nov 2022
Appendix 4D and Financial Report Half Year ended 30 Sep 22
07 Nov 2022
Amplia Appoints Dr Christopher Burns CEO & Managing Director
28 Oct 2022
Quarterly Activities and Cashflow Reports - Sep 2022 Qtr
10 Oct 2022
Notification regarding unquoted securities - ATX
03 Oct 2022
AMP886 Activity in Acute Myeloid Leukemia
14 Sep 2022
AACR Conference Presentation
12 Sep 2022
CEO Resignation
07 Sep 2022
Notification regarding unquoted securities - ATX
07 Sep 2022
Change of Director's Interest Notice - Dr. Warwick Tong
07 Sep 2022
Change of Director's Interest Notice - Dr. Robert Peach
07 Sep 2022
Change of Director's Interest Notice - Dr. Christopher Burns
07 Sep 2022
Change of Director's Interest Notice - Mrs. Jane Bell
06 Sep 2022
Change of Director's Interest Notice - Dr. John Lambert
02 Sep 2022
Notification of cessation of securities - ATX
31 Aug 2022
Amplia Receives $1.8m R&D Tax Incentive
25 Aug 2022
Results of Annual General Meeting
25 Aug 2022
CEO & Managing Director Presentation to AGM
17 Aug 2022
Annual General Meeting - ESOP and New Constitution
17 Aug 2022
Employee Security Ownership Plan
04 Aug 2022
Change of Director's Interest Notice - Dr. Warwick Tong
02 Aug 2022
First Patient Recruited to ACCENT Trial in Pancreatic Cancer
28 Jul 2022
Quarterly Activities and Cashflow Reports - June 2022 Qtr
25 Jul 2022
Presentation at Major Pancreatic Cancer Conference
22 Jul 2022
Notice of Annual General Meeting/Proxy - YE 31 March 2022
07 Jul 2022
Change of Director's Interest Notice - Dr. Chistopher Burns
07 Jul 2022
Change of Director's Interest Notice - Dr. Robert Peach
07 Jul 2022
Change of Director's Interest Notice - Dr. John Lambert
07 Jul 2022
Change of Director's Interest Notice - Dr. Warwick Tong
05 Jul 2022
Notification of cessation of securities - ATX
30 Jun 2022
Application for quotation of securities - ATX
29 Jun 2022
Annual General Meeting to be held Thursday 25 August 2022
24 Jun 2022
Registered Office and Principal Place of Business
09 Jun 2022
Notification of Expiry of Unlisted Options
09 Jun 2022
Application for quotation of securities - ATX
02 Jun 2022
AMP945 Shows Efficacy in Model of Lung Fibrosis
30 May 2022
App 4G - Key to Corporate Governance Disclosures
30 May 2022
Corporate Governance Statement
30 May 2022
Preliminary Final Report and Annual Report YE 31 March 2022
13 May 2022
Amplia Receives Second Ethics Clearance for Phase 2 Trial
12 May 2022
Amplia Presentation to 16th Bioshares Biotech Summit
09 May 2022
AMP945 Pre-IND Meeting Outcome
19 Apr 2022
Quarterly Activities and Cashflow Reports - March 2022 Qtr
06 Apr 2022
Ethics Clearance Phase 2 Trial - Pancreatic Cancer Patients
05 Apr 2022
Notification of cessation of securities - ATX
17 Feb 2022
AMP945 Improves Survival in Human Pancreatic Cancer Model
15 Feb 2022
ATX Abstract accepted for presentation at Cancer Conference
14 Feb 2022
Sale of Unmarketable Parcels of Shares
10 Feb 2022
Change of Director's Interest Notice - Jane Bell
01 Feb 2022
Amplia Investor Presentation - February 2022
24 Jan 2022
Quarterly Activities and Cashflow Reports - Dec 2021 Qtr
19 Jan 2022
Notification regarding unquoted securities - ATX
13 Jan 2022
Amplia Completes Manufacture of AMP945 for Planned Trials
22 Dec 2021
Application for quotation of securities - ATX
22 Dec 2021
Application for quotation of securities - ATX
21 Dec 2021
App 3Y - Change of Director's Interest - Mrs Jane Bell
21 Dec 2021
App 3Y - Change of Director's Interest - Dr. Chris Burns
21 Dec 2021
App 3Y - Change of Director's Interest - Dr. Robert Peach
21 Dec 2021
App 3Y - Change of Director's Interest - Dr. John Lambert
21 Dec 2021
App 3Y - Change of Directors Interest Notice - Dr. W. Tong
21 Dec 2021
Proposed issue of securities - ATX
20 Dec 2021
Update - Application for quotation of securities - ATX
17 Dec 2021
Results of Extraordinary General Meeting
16 Dec 2021
Amplia Provides Updated Investor Presentation
15 Dec 2021
Update - Application for quotation of securities - ATX
14 Dec 2021
Update - Proposed issue of securities - ATX
10 Dec 2021
Entitlement Offer Completed
02 Dec 2021
Amplia Awarded $2.1M R&D Cash Flow Loan
24 Nov 2021
App 4D and Financial Report Half Year ended 30 Sep 2021
19 Nov 2021
Notice of Extraordinary General Meeting - 17 Dec 2021
18 Nov 2021
Summary Results - Successful Phase 1 Clinical Trial AMP945
17 Nov 2021
Inhibition of FAK by AMP945 in Phase 1 Clinical Trial
16 Nov 2021
Becoming a Substantial Holder - Acorn Capital Limited
15 Nov 2021
Application for quotation of securities - ATX
15 Nov 2021
Change in substantial holding
15 Nov 2021
Application for quotation of securities - ATX
12 Nov 2021
Section 708A Cleansing Notice - Share Placement
12 Nov 2021
Blueflag Holding - Change of Interest of Substantial Holder
12 Nov 2021
Application for quotation of securities - ATX
08 Nov 2021
Proposed issue of securities - ATX
08 Nov 2021
Proposed issue of securities - ATX
08 Nov 2021
Capital Raising Investor Presentation
08 Nov 2021
Entitlement Offer Prospectus
08 Nov 2021
Placement and Underwritten Entitlement Offer to Raise $12.4m
04 Nov 2021
Amplia and CRUK agree to Amend Licence Terms - AMP886
04 Nov 2021
Trading Halt
27 Oct 2021
Quarterly Activities and Cashflow Reports - Sep 2021 Qtr
26 Oct 2021
Amplia Appoints New Oncology Clinical Advisor
19 Oct 2021
Amplia Provides Updated Investor Presentation
14 Oct 2021
Amplia Receives $1.1m R&D Tax Incentive
01 Oct 2021
Amplia Appoints New Chief Financial Officer
30 Sep 2021
New Garvan Publication Supports Amplia Phase 2 Design
28 Sep 2021
Proactive Investors Lifesciences Webinar Presentation
27 Sep 2021
Amplia to Present at Proactive Investor Lifesciences Webinar
15 Sep 2021
Phase 2 Trial in First-Line Pancreatic Cancer Patients
15 Sep 2021
Updated Investor Presentation
06 Sep 2021
Change of Director's Interest Notice - Jane Bell
27 Aug 2021
Results of Annual General Meeting
27 Aug 2021
AGM - Chief Executive Officer's Presentation
20 Aug 2021
Annual General Meeting Arrangements
28 Jul 2021
Quarterly Activities and Cashflow Reports and Presentation
26 Jul 2021
Shareholder Update and Presentation
23 Jul 2021
App 4G - Key to Corporate Governance Disclosures
23 Jul 2021
2021 Corporate Governance Statement
23 Jul 2021
Annual Report to Shareholders - YE 31 March 2021
23 Jul 2021
Notice of Annual General Meeting/Proxy Form
21 Jul 2021
Results from Successful Phase 1 Clinical Trial of AMP945
29 Jun 2021
Financial Report YE 31 March 2021 - Audited
28 Jun 2021
Amplia and Garvan Enter Into Collaboration Agreement
25 Jun 2021
Annual General Meeting to be Held 27 August 2021
08 Jun 2021
Change of Director's Interest - Dr. Lambert Exercise Options
07 Jun 2021
Application for quotation of securities - ATX
07 Jun 2021
Application for quotation of securities - ATX
02 Jun 2021
AMP945 Improves Survival in Pancreatic Cancer Model
01 Jun 2021
Application for Quotation of Shares - Options Exercised
31 May 2021
App 4E - Preliminary Final Report YE 31 March 2021
11 May 2021
Change in substantial holding
10 May 2021
Section 708A Cleansing Notice - Share Placement
10 May 2021
Appendix 2A - Application for Quotation of Shares
10 May 2021
Appendix 3G - Notification of Issue of Securties - Options
04 May 2021
Proposed issue of Securities - ATX
04 May 2021
Amplia Announces $3.8m Share Placement
30 Apr 2021
Trading Halt
28 Apr 2021
Preclinical Data Support Development AMP945 Pancreatic Cancer
28 Apr 2021
Quarterly Report and Shareholder Update
22 Apr 2021
Initial Director's Interest Notice - Jane Bell
22 Apr 2021
Shareholder Update and Presentation
20 Apr 2021
ATX FAK Inhibitors Reduce Fibrosis in Animal Model of NASH
15 Apr 2021
Amplia Completes Dosing in Phase 1 Clinical Study of AMP945
12 Apr 2021
Amplia Appoints New Non-Executive Director
25 Mar 2021
Change of Registered Office and Principal Place of Business
24 Mar 2021
Appendix 2A - Exercise of Options
18 Mar 2021
Amplia and Garvan Institute Enter Collaboration Agreement
17 Mar 2021
Amplia Completes Single Dose Study of AMP945
17 Feb 2021
Amplia Initiates Multiple Dose Study of AMP945
16 Feb 2021
Appendix 2A - Exercise of Options
11 Feb 2021
Investor Update - February 2021
28 Jan 2021
Quarterly Activities and Cashflow Reports - Dec 2020 Qtr
11 Jan 2021
Appendix 2A - Exercise of Options
17 Dec 2020
Shareholder Update - 2020 Review
02 Dec 2020
Amplia Receives $0.53m R&D Tax Incentive
27 Nov 2020
Appendix 4D and Financial Report Half Year Ended 30 Sep 2020
24 Nov 2020
Appendix 2A - Allot Shares upon Exercise of Options
02 Nov 2020
Notice ASX LR 3.11.2 - Change of Exercise Price of Options
29 Oct 2020
ATX - Sep 2020 Quarter Activities and Cashflow Reports
21 Oct 2020
Amplia Presentation to Reach Market Services - Meet the CEO
20 Oct 2020
Response to ASX Price Query
08 Oct 2020
First Human Dose in Phase 1 Clinical Trial of AMP945
18 Sep 2020
Change of Director's Interest Notice - Dr. Warwick Tong
18 Sep 2020
Change of Director's Interest Notice - Dr. Robert Peach
18 Sep 2020
Change of Director's Interest Notice - Dr. C. Burns
18 Sep 2020
Section 708A Cleansing Notice - Allotment of Shares
18 Sep 2020
Appendix 2A - Application for Quotation of Shares
18 Sep 2020
Results of Annual General Meeting
18 Sep 2020
CEO Presentation to AGM
08 Sep 2020
Amplia Receives Ethics Clearance to Conduct Phase 1 Trial
02 Sep 2020
Appendix 3G - Notification of Issue of Securities - Options
31 Aug 2020
Amplia Appoints Dr Mark Devlin as Chief Scientific Officer
17 Aug 2020
Notice of Annual General Meeting & Proxy - YE 31 March 2020
06 Aug 2020
Change in Substantial Holding - Blueflag Holdings Pty Ltd
06 Aug 2020
Change in Substantial Holding - Platinum Investment Management Limited
05 Aug 2020
Change of Director Interest - Dr Lambert - Entitlement Offer
05 Aug 2020
Change of Directors Interest - Dr W Tong - Entitlement Offer
04 Aug 2020
Appendix 2A - Retail Entitlement Offer
31 Jul 2020
Appendix 4G - Key to Corporate Governance Disclosures
31 Jul 2020
2020 Corporate Governance Statement
31 Jul 2020
Annual Report to Shareholders - YE 31 March 2020
30 Jul 2020
Entitlement Offer Completed
27 Jul 2020
Quarterly Activities and Cashflow Reports - June 2020
23 Jul 2020
Nucleus Network Appointed to Conduct Phase 1 Clinical Trial
20 Jul 2020
AGM to be held Friday 18 September 2020
14 Jul 2020
Change of Director's Interest Notice - Dr. Warwick Tong
14 Jul 2020
Becoming a substantial holder
14 Jul 2020
Becoming a substantial holder
14 Jul 2020
Change in substantial holding
10 Jul 2020
Appendix 2A - Institutional Entitlement Offer
08 Jul 2020
Entitlement Offer - Despatch of Retail Offer Booklet
03 Jul 2020
Institutional Entitlement Offer Completed
01 Jul 2020
Appendix 3B - Rights Issue
01 Jul 2020
Entitlement Offer Cleansing Notice
01 Jul 2020
Capital Raising - Investor Presentation
01 Jul 2020
Entitlement Offer to Fund Phase 1 Clinical Trial
30 Jun 2020
Preclinical Toxicology Studies Support Phase1 Clinical Trial
29 Jun 2020
Trading Halt
25 Jun 2020
Full Year Statutory Accounts - YE 31 March 2020
02 Jun 2020
Investor Presentation
29 May 2020
Preliminary Final Report - YE 31 March 2020
19 May 2020
FDA Orphan Drug Designation - Idiopathic Pulmonary Fibrosis
28 Apr 2020
Quarterly Activities Report - March 2020 Qtr
28 Apr 2020
App 4C - Quarterly Cash Flow Report - March 2020 Qtr
07 Apr 2020
Shares to be Released from Voluntary Escrow
25 Mar 2020
FDA Awards Orphan Drug Designation for Pancreatic Cancer
13 Feb 2020
Professor Paul Timpson Joins Amplia's SAB
12 Feb 2020
Initial Director's Interest Notice - John Lambert
07 Feb 2020
Final Director's Interest Notice - Behrenbruch
07 Feb 2020
Final Director's Interest Notice - Wilkinson
07 Feb 2020
Final Director's Interest Notice - Cooke
06 Feb 2020
Dr. John Lambert appointed as Managing Director
06 Feb 2020
Board Restructuring
30 Jan 2020
Placement Cleasing Statement
30 Jan 2020
Appendix 4C Cash Flow - Dec 2019 Qtr
28 Jan 2020
Ceasing to be a substantial holder - Behrenbruch
28 Jan 2020
Becoming a substantial holder
24 Jan 2020
Appendix 3B - Placement
20 Jan 2020
Amplia Therapeutics Undertakes Placement
16 Jan 2020
Trading Halt
18 Dec 2019
Change of Registered Office and Principal Place of Business
17 Dec 2019
Shareholder Update / 2019 Review
29 Nov 2019
App 4D - Financial Report Half Year Ended 30 Sep 2019
01 Nov 2019
App 4C - Sep 2019 Qtr Cash Flows Statement
17 Sep 2019
Change of Director's Interest - Dr Robert Peach - Placement
17 Sep 2019
Change of Director's Interest - Dr C Behrenbruch - Placement
17 Sep 2019
Change of Director's Interest - Dr Warwick Tong, Placement
17 Sep 2019
Placement Cleansing Notice
17 Sep 2019
App 3B Placement Shares and Options to Directors and Mgt
02 Sep 2019
Amplia Therapeutics Provides Manufacturing Update
30 Aug 2019
Results of Annual General Meeting
21 Aug 2019
Change of Director's Interest - S Wilkinson - Options Lapsed
12 Aug 2019
Amplia Therapeutics - Quarterly Update
05 Aug 2019
Change of Director's Interest - Dr Warwick Tong Rights Issue
05 Aug 2019
Change of Director's Interest - Dr Chris Burns, Rights Issue
05 Aug 2019
Change of Director's Interest - Andrew Cooke, Rights Issue
31 Jul 2019
Appendix 4C - Quarterly Cash Flow Report - June 2019 Qtr
31 Jul 2019
RightsIssue Participation Supports Clinical-Enabling Studies
25 Jul 2019
Amplia Therapeutics - Bioshares Presentation July 2019
25 Jul 2019
Appendix 4G - Key to Corporate Governance Disclosures
25 Jul 2019
2019 Corporate Governance Statement
25 Jul 2019
Notice of Annual General Meeting/Proxy Form
25 Jul 2019
Annual Report to Shareholders - YE 31 March 2019
23 Jul 2019
Amplia Therapeutics Reports Lead Candidate Preclinical Data
22 Jul 2019
Amplia to present to Bioshares Biotech Summit
09 Jul 2019
Update - July 2019 Newsletter
01 Jul 2019
Letter to Shareholders - Rights Issue
28 Jun 2019
Appendix 3B - Rights Issue
28 Jun 2019
Rights Issue Prospectus
27 Jun 2019
Financial Report Year Ended 31 March 2019
24 Jun 2019
Dr John Lambert appointed as new CEO
17 Jun 2019
Preliminary Rights Issue Details
14 Jun 2019
Placement Cleansing Notice
14 Jun 2019
Appendix 3B - Placement $360k
12 Jun 2019
Capital Raising for Clinical-Enabling Studies
29 May 2019
Preliminary Final Report - Year Ended 31 March 2019
30 Apr 2019
Appendix 4C - Quarterly Statement of Cash Flows
01 Apr 2019
European Patent Completes IP Protection in Major Markets
11 Mar 2019
Amplia Expands Advisory Board
12 Feb 2019
Update - February 2019 Newsletter
29 Nov 2018
App 4D Half Year Accounts 30 Sep 2018
13 Nov 2018
Change of Director's Interest - Wilkinson - Options Expired
07 Nov 2018
Change of Director's Interest Notice - Andrew Cooke
30 Oct 2018
Appendix 4C - quarterly
05 Sep 2018
Amplia Investor Introduction
05 Sep 2018
Change of Name to Amplia Therapeutics Limited - ATX
04 Sep 2018
Change of Director's Interest - Cooke - Options
04 Sep 2018
Change of Director's Interest - Peach - Options
04 Sep 2018
Change of Director's Interest - Wilkinson - Options
04 Sep 2018
Appendix 3B - Options